Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis

Authors:

Abstract
178 episodes of essential thrombocytosis with symptoms of haemorrhage or thrombosis, were treated in 15 patients with melphalan (5 mg/m2 orally during 4 d). An average reduction in the platelet count of 77% was achieved by oral melphalan in 14 responding patients. 1 patient appeared to be refractory to oral therapy, but a decrease of the thrombocyte count was achieved after intravenous administration of melphalan. All responding patients experienced a relief of the thrombocytosis‐associated clinical symptoms. Reduction of the thrombocyte count persisted for 3–4 wk.

This publication has 11 references indexed in Scilit: